PPARγ agonists mitigate inflammatory bowel disease (IBD) symptoms, reduce inflammation, and are effective in multiple models of ulcerative colitis as well as in Crohn’s disease [125,126,127,128,129,130,131,132,133,134,135,136,137,138]. This evidence concerns the gene PPARG and inflammatory bowel disease.